A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for MPX International's Debt-to-EBITDA or its related term are showing as below:
MPXOF's Debt-to-EBITDA is not ranked *
in the Drug Manufacturers industry.
Industry Median: 1.66 * Ranked among companies with meaningful Debt-to-EBITDA only.
MPX International (OTCPK:MPXOF) Debt-to-EBITDA Explanation
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
MPX International Debt-to-EBITDA Related Terms
MPX International Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for MPX International's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MPXOF vs ZTS, CTLT, VTRS: Debt-to-EBITDA Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, MPX International's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MPX International Debt-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, MPX International's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where MPX International's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2022) EBITDA data.
MPX International (MPXOF) has a Debt-to-EBITDA of -2.03 as of Mar. 2022. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on MPX International.
Is MPX International's Debt-to-EBITDA too high?
MPX International's current Debt-to-EBITDA is -2.03.
How does MPX International's Debt-to-EBITDA compare to ZTS and CTLT?
MPX International's Debt-to-EBITDA of -2.03 can be compared against companies in the Drug Manufacturers industry. The industry median Debt-to-EBITDA is 1.66. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.66, based on 685 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on MPX International. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.66 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MPX International's current Debt-to-EBITDA is -2.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MPX International stock overvalued right now?
MPX International (MPXOF) has a current Debt-to-EBITDA of -2.03. The current Debt-to-EBITDA is -2.03. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For MPX International (MPXOF), the current Debt-to-EBITDA is -2.03 as of Mar. 2022. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
MPX International Corp is a diversified cannabis company focused on developing and operating assets across the global medical and adult use and engaged in cultivating, manufacturing and marketing products that include cannabinoids as their primary active ingredient. The firm is organized into three segments: Canada, Europe/Africa, and Asia-Pacific. The Canada operating segment's principal business activities consist of production and sale of cannabis, video learning and engagement, patient counselling and referral services. The Europe/Africa operating segment's consist of the production and sale of cannabis and hemp-related products. The Asia-Pacific consist of the production and sale of cannabis. The majority of the revenue is generated in Canada.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MPXOF has been successfully added to your 